Education
About Us
Working with TipRanks
Follow Us
Mckesson Corp. (MCK)
NYSE:MCK
Earnings Data
Report Date
Jul 30, 2025TBA Not Confirmed
Period Ending
2026 (Q1)Consensus EPS Forecast
8.29Last Year’s EPS
7.88Same Quarter Last Year
Strong Buy
Based on 13 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 4.92%
|Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance with record revenue and EPS growth, strategic acquisitions, and robust shareholder returns. However, there are challenges related to business divestitures, regulatory uncertainties, and the planned separation of the medical surgical segment.Company Guidance
During McKesson's earnings call for the fourth quarter of fiscal 2025, the company reported several key metrics reflecting its strong financial performance and future guidance. Full-year consolidated revenues increased by 16% year-over-year, reaching an unprecedented $359 billion. Adjusted earnings per diluted share stood at $33.05, marking a 20% growth, which surpassed the long-term targets of 12% to 14% EPS growth. McKesson returned $3.5 billion in cash to shareholders and projected fiscal 2026 revenue growth between 11% and 15%, with earnings per diluted share expected to range from $36.75 to $37.55, representing 11% to 14% growth year-over-year. The call also highlighted strategic acquisitions, such as PRISM Vision and Core Ventures, and the intent to separate the medical surgical segment into an independent company to further focus on oncology and biopharma services.Record Revenue Growth
Full-year consolidated revenues grew 16% from the prior year, reaching a record level of $359 billion.
Strong Earnings per Share
Adjusted earnings per diluted share was $33.05, exceeding expectations with a year-over-year EPS growth of 20%.
Strategic Acquisitions
Completed acquisition of a controlling interest in PRISM Vision and pending acquisition of Core Ventures, enhancing oncology and specialty capabilities.
U.S. Pharmaceutical Segment Performance
Double-digit growth in revenue and adjusted operating profits, driven by increased prescription volumes and specialty products.
Prescription Technology Solutions Growth
Segment delivered double-digit growth in adjusted operating profit, supported by demand for access and affordability solutions.
Strong Cash Flow and Shareholder Returns
Generated $5.2 billion in free cash flow and returned $3.5 billion to shareholders.
Fiscal 2026 Guidance
Projected revenue growth of 11% to 15% and EPS growth of 11% to 14% for fiscal 2026.
---
MCK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MCK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $690.25 | $693.46 | +0.47% |
Feb 05, 2025 | $606.23 | $599.08 | -1.18% |
Nov 06, 2024 | $548.08 | $606.15 | +10.60% |
Aug 07, 2024 | $615.34 | $545.59 | -11.34% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Mckesson Corp. (MCK) report earnings?
Mckesson Corp. (MCK) is schdueled to report earning on Jul 30, 2025, TBA Not Confirmed.
What is Mckesson Corp. (MCK) earnings time?
Mckesson Corp. (MCK) earnings time is at Jul 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MCK EPS forecast?
MCK EPS forecast for the fiscal quarter 2026 (Q1) is 8.29.
---